Stuart Holden
CIK: 0001763999
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
UroGen Pharma Ltd.
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Jun 22, 2026URGN
UroGen Pharma Ltd.
Award(A)DirectStock Option (right ot buy)
20K shares- - Nov 26, 2025URGN
UroGen Pharma Ltd.
Exercise(M)Direct2K shares- - Aug 26, 2025URGN
UroGen Pharma Ltd.
Award(A)DirectStock Option (right ot buy)
10K shares- - Aug 26, 2025URGN
UroGen Pharma Ltd.
Award(A)DirectRestricted Stock Unit
8K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 22, 2026 | URGN UroGen Pharma Ltd. | Award(A) Stock Option (right ot buy) | 20,000 | - | - | Direct |
| Nov 26, 2025 | URGN UroGen Pharma Ltd. | Exercise(M) | 2,000 | - | - | Direct |
| Aug 26, 2025 | URGN UroGen Pharma Ltd. | Award(A) Stock Option (right ot buy) | 10,000 | - | - | Direct |
| Aug 26, 2025 | URGN UroGen Pharma Ltd. | Award(A) Restricted Stock Unit | 8,000 | - | - | Direct |
1-4 of 4 transactions
About Holden Stuart
Holden Stuart (SEC CIK 0001763999) files insider reports with the SEC as Director of UroGen Pharma Ltd. (URGN).
Signal8 holds 3 ownership filings by Holden Stuart, all Form 4s, filed between Aug 27, 2025 and Jun 24, 2026. Those filings report 4 transactions, from Aug 26, 2025 to Jun 22, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Holden Stuart's filings is in PRINCETON, NJ.
Recent filings by Holden Stuart
Other insiders filing for UroGen Pharma Ltd. (URGN)
- Degnan Chris, Chief Financial Officer
- Schoenberg Mark, Chief Medical Officer
- Smith Jason Drew, General Counsel
- Robinson James A. Jr., Director
- Wildman Daniel George, Director
- BUTITTA CYNTHIA M, Director